JP5419706B2 - グルコキナーゼアクチベーター - Google Patents

グルコキナーゼアクチベーター Download PDF

Info

Publication number
JP5419706B2
JP5419706B2 JP2009543119A JP2009543119A JP5419706B2 JP 5419706 B2 JP5419706 B2 JP 5419706B2 JP 2009543119 A JP2009543119 A JP 2009543119A JP 2009543119 A JP2009543119 A JP 2009543119A JP 5419706 B2 JP5419706 B2 JP 5419706B2
Authority
JP
Japan
Prior art keywords
alkyl
propanamide
oxopyridin
hetero
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009543119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514677A (ja
JP2010514677A5 (enExample
Inventor
チェルヴァラス、ザカリア
フェン、ジュン
グントゥパッリ、プラスナ
エル． グワルトニー、ステファン
ミウラ、ジョアン
サバト、マーク
タン、ミンナム
ワン、ハキシア
Original Assignee
タケダ カリフォルニア インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タケダ カリフォルニア インコーポレイテッド filed Critical タケダ カリフォルニア インコーポレイテッド
Publication of JP2010514677A publication Critical patent/JP2010514677A/ja
Publication of JP2010514677A5 publication Critical patent/JP2010514677A5/ja
Application granted granted Critical
Publication of JP5419706B2 publication Critical patent/JP5419706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009543119A 2006-12-20 2007-12-17 グルコキナーゼアクチベーター Expired - Fee Related JP5419706B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87092906P 2006-12-20 2006-12-20
US60/870,929 2006-12-20
PCT/US2007/087807 WO2008079787A2 (en) 2006-12-20 2007-12-17 Glucokinase activators

Publications (3)

Publication Number Publication Date
JP2010514677A JP2010514677A (ja) 2010-05-06
JP2010514677A5 JP2010514677A5 (enExample) 2011-02-10
JP5419706B2 true JP5419706B2 (ja) 2014-02-19

Family

ID=39446103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543119A Expired - Fee Related JP5419706B2 (ja) 2006-12-20 2007-12-17 グルコキナーゼアクチベーター

Country Status (4)

Country Link
US (2) US8163779B2 (enExample)
EP (1) EP2091947A2 (enExample)
JP (1) JP5419706B2 (enExample)
WO (1) WO2008079787A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20110130365A1 (en) * 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
WO2010084428A1 (en) 2009-01-20 2010-07-29 Pfizer Inc. Substituted pyrazinone amides
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
JP5750050B2 (ja) 2009-12-04 2015-07-15 大正製薬株式会社 ２−ピリドン化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201406987UA (en) 2012-05-17 2014-12-30 Transtech Pharma Llc Glucokinase activator compositions for the treatment of diabetes
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
ES2641469T3 (es) 2012-11-13 2017-11-10 Nissan Chemical Industries, Ltd. Compuesto de 2-piridona
HK1213780A1 (zh) * 2013-03-04 2016-07-15 Vtv治疗有限责任公司 穩定的葡萄糖激酶活化劑組合物
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3197896B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
EP3197889B1 (de) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN106687458B (zh) * 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
PT3263133T (pt) 2015-02-27 2020-05-21 Univ Kyushu Nat Univ Corp Composto de piridinona e a sua utilização
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
AR112840A1 (es) 2017-09-29 2019-12-18 Bayer Ag 3- fenilquinazolin-4(3h)-onas sustituidas y sus usos
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
IL277811B2 (en) 2018-04-10 2023-12-01 Bayer Pharma AG A consequence of oxopyridine is transformed
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
PE20211790A1 (es) 2018-12-21 2021-09-09 Bayer Ag Derivados de oxopiridina sustituidos
US20220144848A1 (en) 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN120398836A (zh) 2019-11-11 2025-08-01 达纳-法伯癌症研究所股份有限公司 变构egfr抑制剂及其使用方法
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
EP4161640A4 (en) 2020-06-08 2024-01-17 vTv Therapeutics LLC Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
MX2022015739A (es) * 2020-06-09 2023-03-23 Dana Farber Cancer Inst Inc Inhibidores alostericos de egfr y metodos de uso de estos.

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB921315A (en) 1958-03-31 1963-03-20 Wellcome Found The manufacture of 8-aminoalkylamino quinoline derivatives
US3956287A (en) * 1973-11-07 1976-05-11 Richardson-Merrell Inc. 7-[(2-Oxo-1-pyridinyl)acylamino]cephalosporin derivatives
JPS62232555A (ja) 1986-04-02 1987-10-13 Unitika Ltd 酵素センサ
US4959212A (en) 1988-06-22 1990-09-25 Alexandra Stancesco Oxidizing-energizing composition and method for the treatment of diabetes
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
DE4211474A1 (de) * 1992-04-06 1993-10-07 Merck Patent Gmbh Imidazopyridine
US5541060A (en) 1992-04-22 1996-07-30 Arch Development Corporation Detection of glucokinase-linked early-onset non-insulin-dependent diabetes mellitus
EP0616036B1 (en) 1993-03-17 1999-07-28 Unitika Ltd. Process for producing fructose 2,6-disphosphate and purification process thereof
JP3203108B2 (ja) 1993-08-26 2001-08-27 協和メデックス株式会社 グルコース−６−リン酸デヒドロゲナーゼの安定化方法
DE4341665A1 (de) 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
US6486380B1 (en) 1993-12-17 2002-11-26 University Of North Dakota Medical Education Research Foundation Pancreatic β cell hexokinase transgene
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
GB9618934D0 (en) 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
FR2758326B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives de pyridone, leur prepaparation et leur utilisation comme intermediaires de synthese
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7378507B2 (en) 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
ZA988460B (en) 1997-09-17 1999-03-19 Genentech Inc Polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US6894148B2 (en) 1997-11-12 2005-05-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030129691A1 (en) 1998-02-09 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040048332A1 (en) 1998-04-29 2004-03-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20030073188A1 (en) 1998-07-07 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1153131B1 (en) 1999-02-19 2007-09-26 enGene, Inc. Compositions for gene therapy of diabetes
KR20030002292A (ko) 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
US6967019B2 (en) 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
JP4447705B2 (ja) 1999-10-20 2010-04-07 独立行政法人科学技術振興機構 糖尿病発症モデル哺乳動物
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
US20020009779A1 (en) 2000-05-19 2002-01-24 Meyers Rachel A. 50365, a novel hexokinase family member and uses therefor
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US6716582B2 (en) 2000-04-14 2004-04-06 E. I. Du Pont De Nemours And Company Cellular arrays for the identification of altered gene expression
WO2001098454A2 (en) 2000-04-25 2001-12-27 German Human Genome Project Human dna sequences
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
PT1282612E (pt) 2000-05-03 2005-04-29 Hoffmann La Roche Actividades heteroaromaticas da glucoquinase a vase de alcinilo-fenilo
JP3839723B2 (ja) 2000-05-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
DE60134470D1 (de) 2000-05-08 2008-07-31 Hoffmann La Roche Para-amin substituierte phenylamid glukokinase activatoren
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EP1290213A2 (en) 2000-05-31 2003-03-12 Promega Corporation Assay for kinases and phosphatases
CA2412256A1 (en) 2000-06-27 2002-01-03 Curagen Corporation Polynucleotides and polypeptides encoded thereby
AU2002214531A1 (en) 2000-07-03 2002-01-30 Curagen Corporation Proteins and nucleic acids encoding same
EP1303605A2 (en) 2000-07-19 2003-04-23 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
JP2004514420A (ja) 2000-07-20 2004-05-20 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2001287600B2 (en) 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US20040044179A1 (en) 2000-07-25 2004-03-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100709A1 (en) 2000-07-25 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7371817B2 (en) 2000-07-25 2008-05-13 Genentech, Inc. PRO9783 polypeptides
US20030212255A1 (en) 2000-07-26 2003-11-13 Muralidhara Padigaru Novel proteins and nucleic acids encoding same
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
AU2001284651A1 (en) 2000-08-24 2002-03-04 Eli Lilly And Company Secreted proteins and methods of using same
AU2001288390A1 (en) 2000-08-25 2002-03-04 Cor Therapeutics, Inc. Proteins and nucleic acids encoding same
US6346416B1 (en) 2000-08-29 2002-02-12 Isis Pharmaceuticals, Inc. Antisense inhibition of HPK/GCK-like kinase expression
US6849728B1 (en) 2000-08-31 2005-02-01 Wake Forest University Health Sciences GLUT10: a glucose transporter in the type 2 diabetes linked region of chromosome 20Q12-13.1
WO2002023184A1 (en) 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
US20030187201A1 (en) 2000-09-15 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050048483A1 (en) 2000-09-28 2005-03-03 Su Eric Wen Novel secreted proteins and their uses
EP1364016A2 (en) 2000-10-19 2003-11-26 Eli Lilly And Company Secreted proteins and their uses
WO2002057450A2 (en) 2000-11-29 2002-07-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002046409A2 (en) 2000-12-06 2002-06-13 Curagen Corporation Proteins and nucleic acids encoding same
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
ATE316965T1 (de) 2000-12-06 2006-02-15 Hoffmann La Roche Kondensierte heteroaromatische glucokinaseaktivatoren
WO2002064791A2 (en) 2000-12-08 2002-08-22 Curagen Corporation Proteins and nucleic acids encoding same
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
EP1399474A2 (en) 2000-12-15 2004-03-24 Eli Lilly And Company Secreted proteins and their use
JP2005508601A (ja) 2000-12-19 2005-04-07 キュラジェン コーポレイション ポリペプチドおよびそれをコードする核酸
AU2002246808A1 (en) 2000-12-19 2002-08-06 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
ES2170720B1 (es) 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20030170630A1 (en) 2000-12-21 2003-09-11 Alsobrook John P. Proteins and nucleic acids encoding same
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
WO2002053738A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Nouvelles proteines et adn correspondant
US7122345B2 (en) 2001-01-09 2006-10-17 Curagen Corporation Nucleic acid encoding a NOVX13 polypeptide
CA2433742A1 (en) 2001-01-11 2002-07-18 Curagen Corporation Proteins and nucleic acids encoding same
JP4146095B2 (ja) 2001-01-15 2008-09-03 ユニチカ株式会社 耐熱性グルコキナーゼ遺伝子、それを含有する組換えベクター、その組換えベクターを含有する形質転換体及びその形質転換体を用いた耐熱性グルコキナーゼの製造方法
CN1630720A (zh) 2001-01-18 2005-06-22 默克专利有限公司 具有葡糖脑苷脂酶活性的双功能融合蛋白
WO2002081517A2 (en) 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
GB0101447D0 (en) 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
US20040081981A1 (en) 2001-01-31 2004-04-29 Toru Egashira Method of detecting risk factor for onset of diabetes
WO2002068649A2 (en) 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US20040086875A1 (en) 2001-11-05 2004-05-06 Agee Michele L. Novel proteins and nucleic acids encoding same
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002072757A2 (en) 2001-03-08 2002-09-19 Curagen Corporation Novel proteins and nucleic acids encoding same
US20050089852A1 (en) 2001-03-14 2005-04-28 Lee Shao C. Method and compositions for evaluating risk of developing type 2 diabetes in people of chinese descent
JP4602577B2 (ja) 2001-03-15 2010-12-22 積水メディカル株式会社 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002088164A1 (en) 2001-04-26 2002-11-07 Immunex Corporation Human ox2 receptors
AU2002259209A1 (en) 2001-05-11 2002-11-25 Adipogenix, Inc. Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
WO2002097434A1 (en) 2001-05-29 2002-12-05 Syddansk Universitet Proteins in diabetes proteome analysis
AU2002312211A1 (en) 2001-06-01 2002-12-16 Clingenix, Inc. Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
DE60226343T2 (de) 2001-06-08 2009-06-18 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Zur glucoseregulierten produktion von menschlichem insulin in somatischen zelllinien geeignete nukleinsäurekonstrukte
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003047626A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20030023042A1 (en) 2001-12-06 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
DE10162730A1 (de) 2001-12-20 2003-07-03 Degussa Allele des glk-Gens aus coryneformen Bakterien
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
WO2003075845A2 (en) 2002-03-07 2003-09-18 The Forsyth Institute Immunogenicity of glucan binding protein
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
US20030232370A1 (en) 2002-04-22 2003-12-18 Trifiro Mark A. Glucose sensor and uses thereof
DK1501815T3 (da) 2002-04-26 2007-04-02 Hoffmann La Roche Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
JPWO2003097824A1 (ja) 2002-05-16 2005-09-15 萬有製薬株式会社 グルコキナーゼタンパク質の結晶、及びその結晶を用いたドラッグデザイン方法
US20060228706A1 (en) 2002-06-04 2006-10-12 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
WO2003102163A2 (en) 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
US20060074018A1 (en) 2002-06-04 2006-04-06 Metabolex Inc Methods of diagnosing & treating diabetes and insulin resistance
EP1578991A2 (en) 2002-06-05 2005-09-28 Metabolex, Inc. Methods of diagnosing & treating diabetes and insulin resistance
US20060234292A1 (en) 2002-06-05 2006-10-19 Bernard Allan Methods of diagnosing and treating diabetes and insulin resistance
JP2005529603A (ja) 2002-06-13 2005-10-06 メタボレックス インコーポレーティッド 糖尿病を予防、治療、および診断するための組成物および方法
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR100442832B1 (ko) 2002-07-10 2004-08-02 삼성전자주식회사 다중 중합효소 연쇄반응에 의한 ｍｏｄｙ２ 유전자의증폭을 위한 프라이머 세트
AU2003253880A1 (en) 2002-07-15 2004-02-02 Sugen, Inc. Novel kinases
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US20040132679A1 (en) 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US20040108226A1 (en) 2002-10-28 2004-06-10 Constantin Polychronakos Continuous glucose quantification device and method
US20040143110A1 (en) 2002-10-28 2004-07-22 Krolewski Andrzej S. Type 2 diabetes mellitus genes
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
DE10258885A1 (de) 2002-12-17 2004-07-15 Aventis Pharma Deutschland Gmbh Verfahren zur Generierung eines gentechnisch veränderten Organismus
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
WO2004069194A2 (en) 2003-02-03 2004-08-19 The Brigham And Women's Hospital, Inc. Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
US20040180845A1 (en) 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
US20040185548A1 (en) 2003-03-17 2004-09-23 Qun-Sheng Ji Hybrid receptors for efficient assay of modulators of receptor protein-tyrosine kinases
US20040198969A1 (en) 2003-04-01 2004-10-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2004096806A1 (ja) * 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US7179613B2 (en) 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
US20050008691A1 (en) 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP1625112B1 (en) 2003-05-14 2009-07-22 High Point Pharmaceuticals, LLC Novel compounds for treatment of obesity
US20050043391A1 (en) 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
RS20060320A (sr) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
EA011515B1 (ru) 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005030032A2 (en) 2003-09-22 2005-04-07 The Regents Of The University Of Colorado Use of islet glucose-6-phosphatase related protein as a diagnostic tool and therapeutic target for autoimmune diabetes
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
MX2007001650A (es) * 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
BRPI0516219A (pt) * 2004-09-28 2008-08-26 Otsuka Pharma Co Ltd composto de carboestirila
US8034822B2 (en) * 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
CA2644716A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP2044026B1 (en) * 2006-06-22 2014-03-26 Prana Biotechnology Limited Method of treatment of glioma brain tumour
US20110130365A1 (en) * 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls

Also Published As

Publication number Publication date
WO2008079787A8 (en) 2009-07-16
JP2010514677A (ja) 2010-05-06
US20120252814A1 (en) 2012-10-04
US8163779B2 (en) 2012-04-24
US20090105255A1 (en) 2009-04-23
EP2091947A2 (en) 2009-08-26
US8530499B2 (en) 2013-09-10
WO2008079787A3 (en) 2009-02-19
WO2008079787A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
JP5419706B2 (ja) グルコキナーゼアクチベーター
JP5386350B2 (ja) グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5302012B2 (ja) グルコキナーゼ活性剤
JP5513492B2 (ja) グルコキナーゼ活性剤
US8173645B2 (en) Glucokinase activators
JP2009520825A (ja) グルコキナーゼ活性剤
JP5249939B2 (ja) Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
JP2010508307A (ja) Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US8129538B1 (en) Renin inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130919

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131119

LAPS Cancellation because of no payment of annual fees